News › Industry News, Patient Care

Belgium Bans Use of Ozempic for Weight Loss Until Summer

November 15, 2023
Summer sunscreen

Belgium has decided to temporarily ban the use of Novo Nordisk’s diabetes drug Ozempic as a weight loss treatment amid a shortage of the medicine, according to a royal decree published in the country’s Official Gazette on Tuesday.

Ozempic is approved to treat Type 2 diabetes but has increasingly been prescribed “off-label” to treat weight loss because it has the same active ingredient as Novo’s hugely popular – and scarce – anti-obesity drug Wegovy.

In Britain, doctors and prescribers, including private online pharmacies, have been ordered to stop prescribing Ozempic to people who don’t have type 2 diabetes as soon as possible.

They are also banned from starting new patients with type 2 diabetes on the medicine for as long as the shortage lasts.

Read more at Reuters >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Acquisition Lets AI and Operators Learn From Nearly $2 Billion in Annual Aesthetics Transactions
    • Galderma Celebrates 30 Years of Restylane
    • FDA Issues Letter to Evolus Over Jeuveau Social Media Promotion
    • North Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
Advertisement